This discussion examines the key considerations oncologists weigh when choosing between chemotherapy alone or chemotherapy ...
This discussion provides a clear overview of current treatment standards and ongoing challenges in the management of advanced ...
Treatment responses to Xalkori were not affected by PD-L1 expression in patients with advanced non-small cell lung cancer and ROS1 rearrangements. Patients with advanced non-small cell lung cancer ...
Pharmaceutical Technology on MSN
USPTO grants patent to Genprex’s Reqorsa gene therapy
The US Patent and Trademark Office (USPTO) has granted a patent to Genprex for the use of its Reqorsa gene therapy in ...
Longer follow-up in the IMpower010 trial further cemented the value of atezolizumab (Tecentriq) in treating stage II-IIIa non-small cell lung cancer (NSCLC) in patients with tumors expressing PD-L1.
Immune checkpoint therapy, particularly anti-PD-1/PD-L1 immunotherapy, have achieved significant results in the treatment of various tumors. However, most cancer patients show a low response rate to ...
Recently, the research group of Prof. HUANG Qing at Hefei Institutes of Physical Science, Chinese Academy of Sciences developed DNA-aptamer based surface enhanced Raman spectroscopy (SERS) probes for ...
With Bristol Myers Squibb (BMS) now rolling out the SC version of rival nivolumab (Opdivo Qvantig), the shift from 30-minute intravenous (IV) infusion to 5-minute SC injection could be one of the most ...
Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback